Current imaging methods and molecular biomarkers for hepatocellular carcinoma diagnosis: a narrative review.
11 affiliations
- 1School of Bioscience, Faculty of Pharmacy and Biomedical Sciences, MAHSA University, Jenjarom, Malaysia.
- 2Department of Biomedical Sciences, Faculty of Medical and Life Sciences Sunway University, Petaling Jaya, Malaysia.
- 3Sunway Microbiome Centre, Faculty of Medical and Life Sciences Sunway University, Petaling Jaya, Malaysia.
- 4Faculty of Pharmacy, Asian Institute of Medicine, Science and Technology (AIMST) University, Bedong, Malaysia.
- 5School of Pharmacy, Monash University Malaysia, Subang Jaya, Malaysia.
- 6Global Research Cell, Dr. D. Y. Patil Dental College & Hospital, Dr. D. Y. Patil Vidyapeeth (Deemed to be University), Pune, India.
- 7Department of Neonatology, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences, Chennai, India.
- 8Department of Electrical and Electronics Engineering, Dogus University, Umraniye, Istanbul, Türkiye.
- 9Faculty of Chemical Engineering & Technology, Universiti Malaysia Perlis (UniMAP), Arau, Malaysia.
- 10School of Biology, Faculty of Applied Sciences, Universiti Teknologi MARA, Shah Alam, Malaysia.
- 11Collaborative Drug Discovery Research (CDDR), Faculty of Pharmacy, Universiti Teknologi MARA, Puncak Alam Campus, Puncak Alam, Malaysia.
Abstract
Hepatocellular carcinoma (HCC) is one the seventh most prevalent form of cancer in the world and the third highest cause of cancer fatalities in different parts of the world, mostly due to the late diagnosis. and primarily associated with chronic liver diseases. HCC is heavily linked and associated with hepatitis B and C infections, as well as lifestyle factors such as heavy alcohol consumption, obesity, and diabetes. This narrative review critically evaluates current diagnostic approaches for HCC, including imaging modalities, liver biopsy, and established and emerging molecular biomarkers, while highlighting recent advances, existing limitations, and future diagnostic strategies. A narrative literature search was conducted using PubMed, Scopus, Google Scholar, and Web of Science to identify relevant English-language publications from 2009 to 2026. Original research articles, systematic reviews, meta-analyses, and clinical practice guidelines related to HCC diagnosis and surveillance were considered. The search terms covered HCC, imaging modalities, biomarkers, GALAD, GAAD, microRNA, and liquid biopsy. Guidelines from the American Association for the Study of Liver Diseases (AASLD), the European Association for the Study of the Liver (EASL), and the Asian Pacific Association for the Study of the Liver (APASL) were also reviewed. The reviewed evidence indicates that multiphasic computed tomography (CT) and contrast-enhanced magnetic resonance imaging (MRI) remain key imaging modalities for HCC diagnosis. Emerging biomarkers including des-γ-carboxy prothrombin (DCP), fibroblast growth factor 19 (FGF19), various microRNAs (miRNAs), and osteopontin (OPN), circulating microRNAs (miRNAs), show diagnostic potential, particularly when incorporated into multimarker panels or combined with conventional biomarkers such as alpha-fetoprotein (AFP). Artificial intelligence-assisted imaging and multimarker diagnostic models may also support earlier and more accurate detection. However, wider clinical implementation remains limited by insufficient multicentre validation, lack of assay standardization, limited reproducibility, and insufficient cost-effectiveness evidence. Modern diagnostic methods increasingly incorporate these imaging tools alongside molecular markers to yield a more accurate diagnosis and optimal treatment strategy. While liver biopsy remains the gold standard for histopathological confirmation, its invasive nature and associated risks highlight the urgent need for reliable, non-invasive diagnostic alternatives. This review provides insights into the current strategies to diagnose HCC and with an emphasis on innovative diagnostic strategies.
Related
- Clinical applications and recent advances in multimodal image fusion for hepatocellular carcinoma diagnosis: a narrative review.
- Adjuvant immunotherapy after curative-intent treatment for hepatocellular carcinoma: evidence, limitations, and a research framework for molecular residual disease-guided intervention-a narrative review.
- Identification of diagnostic and prognostic biomarkers for hepatocellular carcinoma: a focus on FIGNL1
- Peri-interventional neutrophil extracellular traps and immune surveillance in hepatocellular carcinoma: mechanisms, biomarkers, and recurrence after liver resection or thermal ablation
- Identification of hepatitis B virus-associated membrane proteins as prognostic biomarkers for hepatocellular carcinoma based on retrospective analysis of integrated membrane proteomics
BibTeX
@article{salem2026current,
title = {{Current imaging methods and molecular biomarkers for hepatocellular carcinoma diagnosis: a narrative review.}},
author = {Almadodi Reema Mohammed Salem and Habiba Alaaeldin Mohmed Elhussieni Seada and Yuan Seng Wu and Michelle Felicia Lee and Upeka Bandaranayake and Neeraj Kumar Fuloria and Shivkanya Fuloria and Mahendran Sekar and Vetriselvan Subramaniyan and Subash C B Gopinath and Muhamad Fareez Ismail},
journal = {Journal of gastrointestinal oncology},
year = {2026},
month = sep,
doi = {10.21037/jgo-2026-0538},
url = {https://europepmc.org/article/MED/42996865},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Current imaging methods and molecular biomarkers for hepatocellular carcinoma diagnosis: a narrative review.
AU - Almadodi Reema Mohammed Salem
AU - Habiba Alaaeldin Mohmed Elhussieni Seada
AU - Yuan Seng Wu
AU - Michelle Felicia Lee
AU - Upeka Bandaranayake
AU - Neeraj Kumar Fuloria
AU - Shivkanya Fuloria
AU - Mahendran Sekar
AU - Vetriselvan Subramaniyan
AU - Subash C B Gopinath
AU - Muhamad Fareez Ismail
PY - 2026
DA - 2026/09/28
JO - Journal of gastrointestinal oncology
DO - 10.21037/jgo-2026-0538
UR - https://europepmc.org/article/MED/42996865
AB - Hepatocellular carcinoma (HCC) is one the seventh most prevalent form of cancer in the world and the third highest cause of cancer fatalities in different parts of the world, mostly due to the late diagnosis. and primarily associated with chronic liver diseases. HCC is heavily linked and associated with hepatitis B and C infections, as well as lifestyle factors such as heavy alcohol consumption, obesity, and diabetes. This narrative review critically evaluates current diagnostic approaches for HCC, including imaging modalities, liver biopsy, and established and emerging molecular biomarkers, while highlighting recent advances, existing limitations, and future diagnostic strategies. A narrative literature search was conducted using PubMed, Scopus, Google Scholar, and Web of Science to identify relevant English-language publications from 2009 to 2026. Original research articles, systematic reviews, meta-analyses, and clinical practice guidelines related to HCC diagnosis and surveillance were considered. The search terms covered HCC, imaging modalities, biomarkers, GALAD, GAAD, microRNA, and liquid biopsy. Guidelines from the American Association for the Study of Liver Diseases (AASLD), the European Association for the Study of the Liver (EASL), and the Asian Pacific Association for the Study of the Liver (APASL) were also reviewed. The reviewed evidence indicates that multiphasic computed tomography (CT) and contrast-enhanced magnetic resonance imaging (MRI) remain key imaging modalities for HCC diagnosis. Emerging biomarkers including des-γ-carboxy prothrombin (DCP), fibroblast growth factor 19 (FGF19), various microRNAs (miRNAs), and osteopontin (OPN), circulating microRNAs (miRNAs), show diagnostic potential, particularly when incorporated into multimarker panels or combined with conventional biomarkers such as alpha-fetoprotein (AFP). Artificial intelligence-assisted imaging and multimarker diagnostic models may also support earlier and more accurate detection. However, wider clinical implementation remains limited by insufficient multicentre validation, lack of assay standardization, limited reproducibility, and insufficient cost-effectiveness evidence. Modern diagnostic methods increasingly incorporate these imaging tools alongside molecular markers to yield a more accurate diagnosis and optimal treatment strategy. While liver biopsy remains the gold standard for histopathological confirmation, its invasive nature and associated risks highlight the urgent need for reliable, non-invasive diagnostic alternatives. This review provides insights into the current strategies to diagnose HCC and with an emphasis on innovative diagnostic strategies.
SN - 2078-6891
SN - 2219-679X
ER -